Paratek Pharmaceuticals, a biopharmaceutical company, has received preliminary stockholder approval for its merger agreement with Gurnet Point Capital and Novo Holdings. The definitive agreement involves Paratek’s acquisition by these entities, with final voting results to be reported in a Form 8-K filing with the U.S. Securities and Exchange Commission. Paratek focuses on developing novel therapies for life-threatening diseases and public health threats.
Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”).
Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.